NCT01412398View on ClinicalTrials.gov

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

CompletedOBSERVATIONAL

Enrollment

446

Participants

Timeline

Start Date

April 7, 2009

Primary Completion Date

April 8, 2014

Study Completion Date

September 1, 2016

Conditions

Hyperphosphatemia

Interventions

DRUG

Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Patients in CAPD who have received Fosrenol for hyperphosphatemia

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY